We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
26
DBV Technologies
DBVT
$914M
$71.6M 0.31%
1,461,426
– –
TIL icon
27
Instil Bio
TIL
$51.4M
$69.6M 0.31%
194,685
– –
VERV
28
DELISTED
Verve Therapeutics
VERV
$66.6M 0.29%
1,416,530
– –
VSTM icon
29
Verastem
VSTM
$624M
$66.2M 0.29%
1,790,969
– –
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$65.6M 0.29%
599,110
– –
NBIX icon
31
Neurocrine Biosciences
NBIX
$15.5B
$64.9M 0.29%
676,975
– –
INSM icon
32
Insmed
INSM
$27.5B
$59.4M 0.26%
2,156,001
– –
IMTX icon
33
Immatics
IMTX
$1.22B
$57.5M 0.25%
4,423,731
+140,793
+3% +$1.79M
ADAP
34
DELISTED
Adaptimmune Therapeutics
ADAP
$50.8M 0.22%
9,830,877
– –
RYTM icon
35
Rhythm Pharmaceuticals
RYTM
$7.57B
$50.5M 0.22%
3,863,239
– –
ZYME icon
36
Zymeworks
ZYME
$2.05B
$49.6M 0.22%
1,708,472
– –
TVTX icon
37
Travere Therapeutics
TVTX
$6.19B
$49.5M 0.22%
2,039,772
+1,852,857
+991% +$34M
BLUE
38
DELISTED
bluebird bio
BLUE
$47.8M 0.21%
192,978
+175,455
+1,001% +$50.2M
TLIS
39
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$47.3M 0.21%
504,989
– –
FMTX
40
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$47M 0.21%
2,024,876
– –
MRUS
41
DELISTED
Merus
MRUS
$44.8M 0.2%
2,037,469
– –
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$2.55B
$40.1M 0.18%
444,444
– –
ALKS icon
43
Alkermes
ALKS
$8.11B
$37.9M 0.17%
1,228,170
– –
FLGT icon
44
Fulgent Genetics
FLGT
$548M
$36.1M 0.16%
401,016
– –
JBIO
45
Jade Biosciences
JBIO
$1.36B
$34.7M 0.15%
47,205
+6,389
+16% +$3.58M
ALGS icon
46
Aligos Therapeutics
ALGS
$41.7M
$32.2M 0.14%
83,056
+18,656
+29% +$7.38M
KNSA icon
47
Kiniksa Pharmaceuticals
KNSA
$6.17B
$31.9M 0.14%
2,799,577
– –
KRYS icon
48
Krystal Biotech
KRYS
$10.3B
$31.7M 0.14%
607,735
– –
NGNE icon
49
Neurogene
NGNE
$773M
$27.6M 0.12%
191,087
– –
SYRE icon
50
Spyre Therapeutics
SYRE
$9.39B
$27.1M 0.12%
136,404
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2021 Portfolio in Review

As of Q3 2021, Julian Baker held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Julian Baker added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Julian Baker's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Julian Baker fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Julian Baker's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Julian Baker opened 12 new positions and closed 10 in Q3 2021.
  • Julian Baker's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.